Molecular Cancer Therapeutics: Prospective Clinical Sequencing of Adult Glioma

May 1, 2019

Siyuan Zheng 1 2 3, Kristin Alfaro-Munoz 4, Wei Wei 5, Xiaojing Wang 3, Fang Wang 6, Agda Karina Eterovic 7, Kenna R Mills Shaw 7, Funda Meric-Bernstam 7, Gregory N Fuller 8, Ken Chen 6, Roel G Verhaak 4 2 6 9, Gordon B Mills 7, W K Alfred Yung 4, Shiao-Pei Weathers 4, John F de Groot 1   Abstract Malignant gliomas are a group of intracranial cancers associated with disproportionately high mortality and morbidity. Here, we report ultradeep targeted sequencing of a prospective cohort of 237 […]

Clinical Cancer Research: Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

April 25, 2019

Caitlin D Lowery 1, Michele Dowless 1, Matthew Renschler 1, Wayne Blosser 1, Alle B VanWye 1, Jennifer R Stephens 1, Philip W Iversen 1, Aimee Bence Lin 1, Richard P Beckmann 1, Kateryna Krytska 2, Kristina A Cole 2, John M Maris 2, Douglas S Hawkins 3, Brian P Rubin 4, Raushan T Kurmasheva 5, Peter J Houghton 5, Richard Gorlick 6, E Anders Kolb 7, Min H Kang 8, C Patrick Reynolds 8, Stephen W Erickson 9, Beverly A Teicher 10, Malcolm A Smith 10, Louis F Stancato 11 Abstract Purpose: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA-damaging effects of […]

Pediatric Blood & Cancer: Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts

April 23, 2019

Luke Jones, Hannah McCalmont, Kathryn Evans, Chelsea Mayoh, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith,  Richard B. Lock Abstract Background Denintuzumab mafodotin (SGN‐CD19A) is a CD19‐targeting antibody‐drug conjugate, comprising a monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin F. Since denintuzumab mafodotin has previously shown activity against B‐cell malignancies in early‐stage clinical trials, it […]

Nature: More and more people are living for years after treatment. Researchers should look for ways to identify and ease long-term effects.

April 19, 2019

When Gregory Aune was 16, he wasn’t particularly concerned about the lasting effects of the drugs and radiation that he was given to treat his lymphoma. “I saw kids around me die, so I felt pretty fortunate,” he says. Nearly 30 years later, Aune has a slightly different perspective. He’s still deeply grateful to have […]

RNA: Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development

April 19, 2019

Mitzli X Velasco, Adam Kosti, Gabriela DA Guardia, Marcia C Santos, Allison Tegge, Mei Qiao, Bruna RS Correa, Greco Hernández, Erzsebet Kokovay, Pedro AF Galante, Luiz OF Penalva Abstract RNA-binding proteins (RBPs) and miRNAs are critical gene expression regulators that interact with one another in cooperative and antagonistic fashions. We identified Musashi1 (Msi1) and miR-137 […]

Journal of Virology: Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants

April 17, 2019

Mingkui Zhou, Michael Humbert, Muhammad M. Mukhtar, Hanna B. Scinto, Hemant K. Vyas, Samir K. Lakhashe, Siddappa N. Byrareddy, Gregor Maurer, Swati Thorat, Joshua Owuor, Zhao Lai, Yidong Chen, Anthony Griffiths, Agnès-Laurence Chenine, Sanjeev Gumber, François Villinger, David Montefiori, Ruth M. Ruprecht ABSTRACT Simian-human immunodeficiency virus (SHIV) infection in rhesus macaques (RMs) resembles human immunodeficiency virus type 1 (HIV-1) infection in humans and serves as a tool to evaluate candidate AIDS vaccines. […]

Pediatric Blood & Cancer: Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation

April 11, 2019

Katherine Haines 1, Stephen F Sarabia 2 3, Karla R Alvarez 2 3, Gail Tomlinson 4, Sanjeev A Vasudevan 3 5, Andras A Heczey 3 6, Angshumoy Roy 2 3, Milton J Finegold 2, D Williams Parsons 1 3 6, Sharon E Plon 1 3 6, Dolores López-Terrada 2 3 Abstract Background: Pediatric hepatocellular carcinoma (HCC) is a rare liver tumor in children with a poor prognosis. Comprehensive molecular profiling to understand the underlying genomic drivers of this tumor has not been completed, and it is unclear […]

UT Health SA Newsroom: Greehey cancer researcher receives UT System’s Rising STARs award

April 10, 2019

David Libich, PhD, assistant professor of biochemistry and structural biology in the Long School of Medicine and faculty member of UT Health’s Greehey Children’s Cancer Research Institute, has received a Rising STARs Award from the UT System. The award for early-career investigators comes with a $250,000 grant. Dr. Libich, who began work here in 2017, […]

Nature: Study cancer survivors

April 9, 2019

More and more people are living for years after treatment. Researchers should look for ways to identify and ease long-term effects. When Gregory Aune was 16, he wasn’t particularly concerned about the lasting effects of the drugs and radiation that he was given to treat his lymphoma. “I saw kids around me die, so I […]

The Journal of Clinical Endocrinology & Metabolism: Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease

April 9, 2019

Shahida K Flores, Ziming Cheng, Angela M Jasper, Keiko Natori, Takahiro Okamoto, Akiyo Tanabe, Koro Gotoh, Hirotaka Shibata, Akihiro Sakurai, Takuya Nakai, Xiaojing Wang, Magnus Zethoven, Shiva Balachander, Yuichi Aita, William Young, Jr., Siyuan Zheng, Kazuhiro Takekoshi, Eijiro Nakamura, Richard W Tothill, Ricardo C T Aguiar, Patricia L M Dahia Abstract Context von Hippel-Lindau (VHL) disease, comprising renal cancer, hemangioblastoma, and/or pheochromocytoma (PHEO), is caused by missense or truncating variants of the VHL tumor-suppressor gene, which […]